COST-EFFECTIVENESS OF SUBCUTANEOUS VERSUS INTRAMUSCULAR INTERFERON BETA-1A IN PORTUGAL BASED ON THE FINDINGS OF COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

被引：0
|
作者：
Silverio, N. [1 ]
Sequeira, L. [1 ]
Meletiche, D. [2 ]
机构：
[1] Merck SA, Alges, Portugal
[2] EMD Serono, Rockland, ME USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.897
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND43
引用
收藏
页码：A398 / A398
页数：1
相关论文
共 50 条
  • [41] COST-UTILITY ANALYSIS OF PEGYLATED INTERFERON BETA-1A VERSUS INTERFERONS BETA-1A AND BETA-1B IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A194
  • [42] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
  • [43] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Xinke Zhang
    Joel W. Hay
    Xiaoli Niu
    CNS Drugs, 2015, 29 : 71 - 81
  • [44] A BUDGET IMPACT ANALYSIS OF THE COCHRANE COLLABORATION REVIEW OF FIRST-LINE TREATMENTS FOR RELAPSING-REMITTIMG MULTIPLE SCLEROSIS
    Meletiche, D. M.
    Park, S.
    Rutkowski, T.
    Chowdhury, C. A.
    Beckerman, R.
    VALUE IN HEALTH, 2014, 17 (03) : A58 - A58
  • [45] Effects of immunomodulatory treatment with subcutaneous interferon beta-1a oncognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis
    Patti, F.
    Amato, M. P.
    Bastianello, S.
    Caniatti, L.
    Di Monte, E.
    Ferrazza, P.
    Goretti, B.
    Gallo, P.
    Morra, V. Brescia
    Lo Fermo, S.
    Picconi, O.
    Tola, M. R.
    Trojano, M.
    MULTIPLE SCLEROSIS, 2010, 16 (01): : 68 - 77
  • [46] Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis
    Zhang, Xinke
    Hay, Joel W.
    Niu, Xiaoli
    CNS DRUGS, 2015, 29 (01) : 71 - 81
  • [47] Effects of two different doses of subcutaneous interferon beta-1a treatment on cognition in patients with early relapsing-remitting multiple sclerosis
    Patti, F.
    Amato, M. P.
    Caniatti, L.
    Di Monte, E.
    Ferrazza, P.
    Goretti, B.
    Lo Fermo, S.
    Picconi, O.
    Tola, M. R.
    Trojano, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S56 - S56
  • [48] Oral drugs versus interferon-beta or glatiramer acetate as first-line disease modifying therapy in relapsing-remitting multiple sclerosis
    Benkert, P.
    Lienert, C.
    Lorscheider, J.
    Hanni, P.
    Decard, B.
    Kuhle, J.
    Derfuss, T.
    Kappos, L.
    Yaldizli, O.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 684 - 684
  • [49] Effect of daclizumab HYP versus intramuscular interferon beta-1a on no evidence of disease activity in patients with relapsing-remitting multiple sclerosis: analysis of the DECIDE study
    Kappos, L.
    Havrdova, E.
    Giovannoni, G.
    Khatri, B. O.
    Gauthier, S. A.
    Greenberg, S.
    Wang, P.
    Elkins, J.
    Barbato, L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 22 - 22
  • [50] A Matching-adjusted Indirect Comparison of Clinical Effectiveness of Subcutaneous Peginterferon Beta-1a and Intramuscular Interferon Beta-1a for the Treatment of Relapsing Multiple Sclerosis
    You, Xiaojun
    Scott, Thomas
    Shang, Shulian
    Evilevitch, Vladimir
    Sabetella, Guido
    Werneburg, Brian
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 415 - 415
12345